GlassScriptPhysician profile
John Jr Frese
NPI 1457316382
$11,301.95
in general payments reported to CMS, 2019-2025
43 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,935 · 2020: $364 · 2021: $671 · 2022: $190 · 2023: $2,739 · 2024: $2,947 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,128 · Education: $13.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,127.95 |
| Education | $13.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,030.99 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,683.54 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $959.34 | 2023-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $940.44 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $742.91 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $703.70 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $671.64 | 2019-2025 | |
| Ardelyx, INC. | $520.49 | 2022-2025 | Ibsrela |
| Celgene Corporation | $255.12 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $234.55 | 2019-2024 | Ocaliva |
| Pfizer INC. | $203.58 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $199.31 | 2021-2024 | Linzess |
| Lilly USA, LLC | $166.91 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $159.98 | 2019-2024 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $134.59 | 2025 | Rezdiffra |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $131.85 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $130.15 | 2019-2024 | Rebyota |
| Ucb, INC. | $127.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $116.61 | 2019-2021 | |
| Shionogi INC | $112.17 | 2019-2020 | |
| Mml US, INC. | $110.05 | 2023 | Reactiv8 |
| Fresenius Kabi USA, LLC | $108.85 | 2023-2024 | Idacio |
| Exact Sciences Corporation | $95.31 | 2024-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $84.31 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $56.44 | 2024-2025 | Zenpep |
| Pentax of America, INC. | $56.16 | 2020-2025 | Pentax Medical, C2 Cryoballoon, Inspira |
| Concordia Pharmaceuticals INC. | $55.17 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $53.88 | 2024 | Iqirvo |
| Genzyme Corporation | $51.06 | 2024-2025 | |
| Alfasigma USA, INC. | $45.93 | 2020 | |
| Allergan, INC. | $44.47 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $42.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.48 | 2024 | Cyltezo |
| Cumberland Pharmaceuticals, INC. | $36.99 | 2023 | Kristalose |
| Redhill Biopharma INC. | $35.64 | 2021-2023 | Talicia |
| Fujifilm Healthcare Americas Corporation | $32.58 | 2023 | Fujifilm |
| Biocon Biologics INC | $29.97 | 2025 | Yesintek |
| Amgen INC. | $26.45 | 2025 | |
| Novo Nordisk INC | $24.97 | 2025 | Wegovy |
| Shire North American Group INC | $17.09 | 2019 | |
| Romark Laboratories, Lc | $16.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Frese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.